By VC News Daily
NEW YORK, NY, Envisagenics, an AI-driven revenue generating biotechnology company, announced a Series B fundraising round.
Envisagenics, an AI-driven revenue generating biotechnology company focused on discovery and development of novel RNA splicing therapeutics, announced a Series B fundraising round with participation from existing investors Third Kind Venture Capital, Empire State Development and Red Cell Partners, and new strategic investor Bristol Myers Squibb (NYSE: BMY). Bristol Myers Squibb previously entered into an oncology research collaboration with Envisagenics in 2022.
(c) by Massinvestor, Inc. For contact info, please check out our about page.